Table 2.
Baseline-TNF | ||||
---|---|---|---|---|
TNF-low (n=94) | TNF-int (n=191) | TNF-high (n=42) | p Value (overall) | |
DAS28-CRP | 5.3 (4.9, 5.9) | 5.5 (5.0, 6.2) | 5.9 (5.2, 6.7) | 0.002 |
DAS28-ESR | 5.9 (5.5, 6.4) | 6.2 (5.7, 6.8) | 6.8 (6.2, 7.3) | <0.001 |
TJC, 68 joints | 14.0 (10.0, 21.0) | 15.0 (11.0, 23.0) | 16.5 (12.0, 23.0) | 0.153 |
SJC, 66 joints | 11.0 (8.0, 16.0) | 13.0 (9.0, 17.0) | 12.5 (10.0, 18.0) | 0.041 |
Patient pain VAS, mm | 49.0 (37.0, 65.0) | 58.0 (40.0, 72.0) | 68.5 (46.0, 88.0) | <0.001 |
Patient global VAS, mm | 51.0 (36.0, 64.0) | 56.0 (36.0, 72.0) | 65.0 (43.0, 86.0) | 0.016 |
Physician global VAS, mm | 62.0 (50.0, 75.0) | 65.0 (49.0, 77.0) | 72.0 (51.0, 82.0) | 0.081 |
CRP (mg/dl) | 2.0 (1.0, 3.9) | 2.4 (1.2, 3.9) | 2.8 (1.4, 5.8) | 0.028 |
ESR (mm/h) | 46.0 (33.0, 65.0) | 53.0 (35.0, 72.0) | 67.5 (40.0, 89.0) | 0.001 |
HAQ | 1.0 (0.5, 1.4) | 1.1 (0.9, 1.6) | 1.4 (1.0, 2.1) | 0.002 |
TSS | 37.0 (10.5, 76.0)* | 36.0 (12.5, 72.3)† | 22.5 (13.0, 56.0) | 0.960 |
Estimated yearly progression of TSS, point/year | 5.8 (2.8, 12.0)* | 6.3 (3.4, 11.3)† | 5.5 (2.5, 10.0) | 0.833 |
RF value, IU/ml | 85 (27, 215) | 81 (37, 167) | 238 (126, 554) | 0.007 |
Anti-CCP antibodies value, IU/ml | 91 (17, ≥100) | ≥100 (30, ≥100) | ≥100 (≥100, ≥100) | 0.012 |
MMP-3 value, ng/ml | 205 (105, 377) | 216 (102, 391) | 268 (114, 640) | 0.214 |
Data in baseline value are median (IQR).
Baseline disease activities were evaluated in the patients enrolled in the RISING study (n=327). The associations of baseline-tumour necrosis factor alpha (TNF) with baseline disease activities were analysed in the three groups (TNF-low, TNF-int and TNF-high patients) employing the Kendall rank correlation coefficient.
n=93.
n=190.
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; MMP-3, matrix metalloproteinase 3; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; TSS, total modified Sharp score; VAS, visual analogue scale.